Purinergic signalling explained

Purinergic signalling (or signaling: see American and British English differences) is a form of extracellular signalling mediated by purine nucleotides and nucleosides such as adenosine and ATP. It involves the activation of purinergic receptors in the cell and/or in nearby cells, thereby regulating cellular functions.

It was proposed after Adenosine triphosphate (ATP) was identified in 1970 as the transmitter responsible for non-adrenergic, noncholinergic neurotransmission. Nowadays is it known that ATP acts a cotransmitter in most, if not all, nerves in the central and peripheral nervous system.[1]

Receptors for adenosine (called P1) and for ATP and ADP (called P2) were distinguished in 1978. Later, the P2 receptors were subdivided into P2X and P2Y families based on their different mechanisms. In the early 1990s, when the receptors to purines and pyrimidines were cloned and characterized, numerous subtypes of P1 and P2 receptors were discovered.[2]

The purinergic signalling complex of a cell is sometimes referred to as the “purinome”.[3]

Background

Evolutionary origins

Purinergic receptors, represented by several families, are among the most abundant receptors in living organisms and appeared early in evolution.[4]

Among invertebrates, the purinergic signalling system has been found in bacteria, amoeba, ciliates, algae, fungi, anemones, ctenophores, platyhelminthes, nematodes, crustacea, molluscs, annelids, echinoderms, and insects.[5] In green plants, extracellular ATP and other nucleotides induce an increase in the cytosolic concentration of calcium ions, in addition to other downstream changes that influence plant growth and modulate responses to stimuli.[6] In 2014, the first purinergic receptor in plants, DORN1, was discovered.[7]

The primitive P2X receptors of unicellular organisms often share low sequence similarity with those in mammals, yet they still retain micromolar sensitivity to ATP. The evolution of this receptor class is estimated to have occurred over a billion years ago.[8]

Molecular mechanisms

Generally speaking, all cells have the ability to release nucleotides. In neuronal and neuroendocrinal cells, this mostly occurs via regulated exocytosis. Released nucleotides can be hydrolyzed extracellularly by a variety of cell surface-located enzymes referred to as ectonucleotidases. The purinergic signalling system consists of transporters, enzymes and receptors responsible for the synthesis, release, action, and extracellular inactivation of (primarily) ATP and its extracellular breakdown product adenosine.[9] The signalling effects of uridine triphosphate (UTP) and uridine diphosphate (UDP) are generally comparable to those of ATP.[10]

Purinergic receptors

Purinergic receptors are specific classes of membrane receptors that mediate various physiological functions such as the relaxation of gut smooth muscle, as a response to the release of ATP or adenosine. There are three known distinct classes of purinergic receptors, known as P1, P2X, and P2Y receptors. Cell signalling events initiated by P1 and P2Y receptors have opposing effects in biological systems.

Name Activation Class - G protein-coupled receptors - nucleotides G protein-coupled receptors - ligand-gated ion channel

Nucleoside transporters

Nucleoside transporters (NTs) are a group of membrane transport proteins which transport nucleoside substrates including adenosine across the membranes of cells and/or vesicles. NTs are considered to be evolutionarily ancient membrane proteins and are found in many different forms of life. There are two types of NTs:

The extracellular concentration of adenosine can be regulated by NTs, possibly in the form of a feedback loop connecting receptor signaling with transporter function.[11]

Ectonucleotidases

Released nucleotides can be hydrolyzed extracellularly by a variety of cell surface-located enzymes referred to as ectonucleotidases that control purinergic signalling. Extracellular nucleoside triphosphates and diphosphates are substrates of the ectonucleoside triphosphate diphosphohydrolases (E-NTPDases), the ectonucleotide pyrophosphatase/phosphodiesterases (E-NPPs) and alkaline phosphatases (APs). Extracellular AMP is hydrolyzed to adenosine by ecto-5'-nucleotidase (eN) as well as by APs. In any case, the final product of the hydrolysis cascade is the nucleoside.[12] [13]

Pannexins

The Pannexin-1 channel (PANX1) is an integral component of the P2X/P2Y purinergic signaling pathway and the key contributor to pathophysiological ATP release.[14] For example, the PANX1 channel, along with ATP, purinergic receptors, and ectonucleotidases, contribute to several feedback loops during the inflammatory response.[15]

Purinergic signalling in humans

Circulatory system

In the human heart, adenosine functions as an autacoid in the regulation of various cardiac functions such as heart rate, contractility, and coronary flow. There are currently four types of adenosine receptors found in the heart.[16] After binding onto a specific purinergic receptor, adenosine causes a negative chronotropic effect due to its influence on cardiac pacemakers. It also causes a negative dromotropic effect through the inhibition of AV-nodal conduction.[17] From the 1980s onwards, these effects of adenosine have been used in the treatment of patients with supraventricular tachycardia.[18]

The regulation of vascular tone in the endothelium of blood vessels is mediated by purinergic signalling. A decreased concentration of oxygen releases ATP from erythrocytes, triggering a propagated calcium wave in the endothelial layer of blood vessels and a subsequent production of nitric oxide that results in vasodilation.[19] [20]

During the blood clotting process, adenosine diphosphate (ADP) plays a crucial role in the activation and recruitment of platelets and also ensures the structural integrity of thrombi. These effects are modulated by the P2RY1 and the P2Y12 receptors. The P2RY1 receptor is responsible for shape change in platelets, increased intracellular calcium levels and transient platelet aggregation, while the P2Y12 receptor is responsible for sustained platelet aggregation through the inhibition of adenylate cyclase and a corresponding decrease in cyclic adenosine monophosphate (cAMP) levels. The activation of both purinergic receptors is necessary to achieve sustained hemostasis.[21] [22]

Digestive system

In the liver, ATP is constantly released during homeostasis and its signalling via P2 receptors influences bile secretion as well as liver metabolism and regeneration.[23] P2Y receptors in the enteric nervous system and at intestinal neuromuscular junctions modulate intestinal secretion and motility.[24]

Endocrine system

Cells of the pituitary gland secrete ATP, which acts on P2Y and P2X purinoreceptors.[25]

Immune system

Autocrine purinergic signalling is an important checkpoint in the activation of white blood cells. These mechanisms either enhance or inhibit cell activation based on the purinergic receptors involved, allowing cells to adjust their functional responses initiated by extracellular environmental cues.[26]

Like most immunomodulating agents, ATP can act either as an immunosuppressive or an immunostimulatory factor, depending on the cytokine microenvironment and the type of cell receptor.[27] In white blood cells such as macrophages, dendritic cells, lymphocytes, eosinophils, and mast cells, purinergic signalling plays a pathophysiological role in calcium mobilization, actin polymerization, release of mediators, cell maturation, cytotoxicity, and apoptosis.[28] Large increases in extracellular ATP that are associated with cell death serve as a "danger signal" in the inflammatory processes.[29]

In neutrophils, tissue adenosine can either activate or inhibit various neutrophil functions, depending on the inflammatory microenvironment, the expression of adenosine receptors on the neutrophil, and the affinity of these receptors for adenosine. Micromolar concentrations of adenosine activate A2A and A2B receptors. This inhibits the release of granules and prevents oxidative burst. On the other hand, nanomolar concentrations of adenosine activate A1 and A3 receptors, resulting in neutrophilic chemotaxis towards inflammatory stimuli. The release of ATP and an autocrine feedback through P2RY2 and A3 receptors are signal amplifiers.[30] [31] Hypoxia-inducible factors also influence adenosine signalling.[18]

Nervous system

In the central nervous system (CNS), ATP is released from synaptic terminals and binds to a plethora of ionotropic and metabotropic receptors. It has an excitatory effect on neurones, and acts as a mediator in neuronal–glial communications.[32] Both adenosine and ATP induce astrocyte cell proliferation. In microglia, P2X and P2Y receptors are expressed. The P2Y6 receptor, which is primarily mediated by uridine diphosphate (UDP), plays a significant role in microglial phagoptosis, while the P2Y12 receptor functions as a specialized pattern recognition receptor. P2RX4 receptors are involved in the CNS mediation of neuropathic pain.[33]

In the peripheral nervous system, Schwann cells respond to nerve stimulation and modulate the release of neurotransmitters through mechanisms involving ATP and adenosine signalling.[34] In the retina and the olfactory bulb, ATP is released by neurons to evoke transient calcium signals in several glial cells such as Muller glia and astrocytes. This influences various homeostatic processes of the nervous tissue including volume regulation and the control of blood flow. Although purinergic signaling has been connected to pathological processes in the context of neuron-glia communication, it has been revealed, that this is also very important under physiological conditions. Neurons possess specialised sites on their cell bodies, through which they release ATP (and other substances), reflecting their "well-being". Microglial processes specifically recognize these purinergic somatic-junctions, and monitor neuronal functions by sensing purine nucleotides via their P2Y12-receptors. In case of neuronal overactivation or injury, microglial processes respond with an increased coverage of neuronal cell bodies, and exert robust neuroprotective effects.[35] These purinergic somatic-junctions have also been shown to be important for microglia to control neuronal development. [36] Calcium signaling evoked by purinergic receptors contributes to the processing of sensory information.[37]

During neurogenesis and in early brain development, ectonucleotidases often downregulate purinergic signalling in order to prevent the uncontrolled growth of progenitor cells and to establish a suitable environment for neuronal differentiation.[38]

Purinergic signalling, and in particular tissue-injury induced ATP-release is very important for the rapid and robust phenotype changes of microglia. [39]

Renal system

In the kidneys, the glomerular filtration rate (GFR) is regulated by several mechanisms including tubuloglomerular feedback (TGF), in which an increased distal tubular sodium chloride concentration causes a basolateral release of ATP from the macula densa cells. This initiates a cascade of events that ultimately brings GFR to an appropriate level.[40] [41]

Respiratory system

ATP and adenosine are crucial regulators of mucociliary clearance.[42] The secretion of mucin involves P2RY2 receptors found on the apical membrane of goblet cells.[42] Extracellular ATP signals acting on glial cells and the neurons of the respiratory rhythm generator contribute to the regulation of breathing.[43]

Skeletal system

In the human skeleton, nearly all P2Y and P2X receptors have been found in osteoblasts and osteoclasts. These receptors enable the regulation of multiple processes such as cell proliferation, differentiation, function, and death.[44] The activation of the adenosine A1 receptor is required for osteoclast differentiation and function, whereas the activation of the adenosine A2A receptor inhibits osteoclast function. The other three adenosine receptors are involved in bone formation.[45]

Pathological aspects

Alzheimer's disease

In Alzheimer's disease (AD), the expression of A1 and A2A receptors in the frontal cortex of the human brain is increased, while the expression of A1 receptors in the outer layers of hippocampal dentate gyrus is decreased.[38]

Asthma

In the airways of patients with asthma, the expression of adenosine receptors is upregulated. Adenosine receptors affect bronchial reactivity, endothelial permeability, fibrosis, angiogenesis and mucus production.[46]

Bone diseases

Purinergic signalling is involved in the pathophysiology of several bone and cartilage diseases such as osteoarthritis, rheumatoid arthritis, and osteoporosis.[47] Single-nucleotide polymorphisms (SNPs) in the P2RX7 receptor gene are associated with an increased risk of bone fracture.[44]

Cancer

The P2RX7 receptor is overexpressed in most malignant tumors.[48] The expression of the adenosine A2A receptor on endothelial cells is upregulated in the early stages of human lung cancer.[49]

Cardiovascular diseases

Formation of foam cells is inhibited by adenosine A2A receptors.[50]

Chronic obstructive pulmonary disease

Abnormal levels of ATP and adenosine are present in the airways of patients with chronic obstructive pulmonary disease.[51] [52]

Erectile disorders

The release of ATP increases adenosine levels and activates nitric oxide synthase, both of which induces the relaxation of the corpus cavernosum penis. In male patients with vasculogenic impotence, dysfunctional adenosine A2B receptors are associated with the resistance of the corpus cavernosum to adenosine. On the other hand, excess adenosine in penile tissue contributes to priapism.[53] [54]

Fibrosis

The bronchoalveolar lavage (BAL) fluid of patients with idiopathic pulmonary fibrosis contains a higher concentration of ATP than that of control subjects. Persistently elevated concentrations of adenosine beyond the acute-injury phase leads to fibrotic remodelling.[55] Extracellular purines modulate fibroblast proliferation by binding onto adenosine receptors and P2 receptors to influence tissue structure and pathologic remodeling.[56]

Graft-versus-host disease

Following tissue injury in patients with Graft-versus-host disease (GVHD), ATP is released into the peritoneal fluid. It binds onto the P2RX7 receptors of host antigen-presenting cells (APCs) and activates the inflammasomes. As a result, the expression of co-stimulatory molecules by APCs is upregulated. The inhibition of the P2X7 receptor increases the number of regulatory T cells and decreases the incidence of acute GVHD.[57]

Therapeutic interventions

Current

AcupunctureMechanical deformation of the skin by acupuncture needles appears to result in the release of adenosine.[58] [59] A 2014 Nature Reviews Cancer review article found that the key mouse studies that suggested acupuncture relieves pain via the local release of adenosine, which then triggered close-by A1 receptors "caused more tissue damage and inflammation relative to the size of the animal in mice than in humans, such studies unnecessarily muddled a finding that local inflammation can result in the local release of adenosine with analgesic effect."[60] The anti-nociceptive effect of acupuncture may be mediated by the adenosine A1 receptor.[61] [62] [63] Electroacupuncture may inhibit pain by the activation of a variety of bioactive chemicals through peripheral, spinal, and supraspinal mechanisms of the nervous system.[64]
Anti-inflammatory drugsMethotrexate, which has strong anti-inflammatory properties, inhibits the action of dihydrofolate reductase, leading to an accumulation of adenosine. On the other hand, the adenosine-receptor antagonist caffeine reverses the anti-inflammatory effects of methotrexate.[65]
Anti-platelet drugs

Many anti-platelet drugs such as Prasugrel, Ticagrelor, and Ticlopidine are adenosine diphosphate (ADP) receptor inhibitors. Before the expiry of its patent, the P2Y12 receptor antagonist Clopidogrel (trade name: Plavix) was the second most prescribed drug in the world. In 2010 alone, it generated over US$9 billion in global sales.[66]

BronchodilatorsTheophylline was originally used as a bronchodilator, although its usage has declined due to several side effects such as seizures and cardiac arrhythmias caused by adenosine A1 receptor antagonism.[67]
Herbal medicineSeveral herbs used in Traditional Chinese medicine contain drug compounds that are antagonists of P2X purinoreceptors. The following table provides an overview of these drug compounds and their interaction with purinergic receptors.
Herb Drug compound Physiologic effects on purinergic receptors
Many
Ligusticum wallichii
  • Reduction of thermal and mechanical hyperalgesia via P2RX3 antagonism[71]
Kudzu
  • Reduction of chronic neuropathic pain via P2RX3 and P2X2/3 antagonism[72]
Rheum officinale
Rhubarb
  • Induction of necrosis in human liver cancer cells via a decrease in ATP levels.[75]
Vasodilators

Regadenoson, a vasodilator which acts on the adenosine A2A receptor, was approved by the United States Food and Drug Administration in 2008 and is currently widely used in the field of cardiology.[76] [77] Both adenosine and dipyridamole, which act on the A2A receptor, are used in myocardial perfusion imaging.[78]

Proposed

Purinergic signalling is an important regulatory mechanism in a wide range of inflammatory diseases. It is understood that shifting the balance between purinergic P1 and P2 signalling is an emerging therapeutic concept that aims to dampen pathologic inflammation and promote healing. The following list of proposed medications is based on the workings of the purinergic signalling system:

History

The earliest reports of purinergic signalling date back to 1929, when the Hungarian physiologist Albert Szent-Györgyi observed that purified adenine compounds produced a temporary reduction in heart rate when injected into animals.[81] [82]

In the 1960s, the classical view of autonomic smooth muscle control was based upon Dale's principle, which asserts that each nerve cell can synthesize, store,and release only one neurotransmitter. It was therefore assumed that a sympathetic neuron releases noradrenaline only, while an antagonistic parasympathetic neuron releases acetylcholine only. Although the concept of cotransmission gradually gained acceptance in the 1980s, the belief that a single neuron acts via a single type of neurotransmitter continued to dominate the field of neurotransmission throughout the 1970s.[83]

Beginning in 1972, Geoffrey Burnstock ignited decades of controversy after he proposed the existence of a non-adrenergic, non-cholinergic (NANC) neurotransmitter, which he identified as ATP after observing the cellular responses in a number of systems exposed to the presence of cholinergic and adrenergic blockers.[84] [85] [86]

Burnstock's proposal was met with criticism, since ATP is an ubiquitous intracellular molecular energy source[87] so it seemed counter-intuitive that cells might also actively release this vital molecule as a neurotransmitter. After years of prolonged scepticism, however, the concept of purinergic signalling was gradually accepted by the scientific community.[88]

Today, purinergic signalling is no longer considered to be confined to neurotransmission, but is regarded as a general intercellular communication system of many, if not all, tissues.[88]

See also

Notes and References

  1. Burnstock . Geoffrey . March 2012 . Purinergic signalling: Its unpopular beginning, its acceptance and its exciting future . BioEssays . en . 34 . 3 . 218–225 . 10.1002/bies.201100130 . 0265-9247.
  2. Burnstock . Geoffrey . January 2018 . Purine and purinergic receptors . Brain and Neuroscience Advances . en . 2 . 239821281881749 . 10.1177/2398212818817494 . 2398-2128 . 7058212 . 32166165.
  3. Volonté . Cinzia . D’Ambrosi . Nadia . Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters: The purinome . FEBS Journal . 2009 . 276 . 2 . 318–329 . 10.1111/j.1742-4658.2008.06793.x. 19076212 . free .
  4. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H . Purinergic signalling in the nervous system: an overview . Trends in Neurosciences . 32 . 1 . 19–29 . January 2009 . 19008000 . 10.1016/j.tins.2008.10.001 . 7653609 .
  5. Burnstock G, Verkhratsky A . Evolutionary origins of the purinergic signalling system . Acta Physiologica . 195 . 4 . 415–47 . April 2009 . 19222398 . 10.1111/j.1748-1716.2009.01957.x . 12644331 .
  6. Roux SJ, Steinebrunner I . Extracellular ATP: an unexpected role as a signaler in plants . Trends in Plant Science . 12 . 11 . 522–7 . November 2007 . 17928260 . 10.1016/j.tplants.2007.09.003 .
  7. Cao Y, Tanaka K, Nguyen CT, Stacey G . Extracellular ATP is a central signaling molecule in plant stress responses . Current Opinion in Plant Biology . 20 . 82–7 . August 2014 . 24865948 . 10.1016/j.pbi.2014.04.009 .
  8. Fountain SJ . Primitive ATP-activated P2X receptors: discovery, function and pharmacology . Frontiers in Cellular Neuroscience . 7 . 247 . December 2013 . 24367292 . 10.3389/fncel.2013.00247 . 3853471 . free .
  9. Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M . The role of purinergic signaling in depressive disorders . Neuropsychopharmacologia Hungarica . 14 . 4 . 231–8 . December 2012 . 23269209 .
  10. Corriden R, Insel PA . Basal release of ATP: an autocrine-paracrine mechanism for cell regulation . Science Signaling . 3 . 104 . re1 . January 2010 . 20068232 . 3085344 . 10.1126/scisignal.3104re1 . Cells release other nucleotides [for example, uridine triphosphate (UTP) and related molecules such as uridine diphosphate (UDP) sugars] that have actions akin to those of ATP .
  11. Dos Santos-Rodrigues A, Grañé-Boladeras N, Bicket A, Coe IR . Nucleoside transporters in the purinome . Neurochemistry International . 73 . 229–37 . July 2014 . 24704797 . 10.1016/j.neuint.2014.03.014 . 24292160 .
  12. Book: Kukulski F, Lévesque SA, Sévigny J . Pharmacology of Purine and Pyrimidine Receptors . Impact of ectoenzymes on p2 and p1 receptor signaling . Advances in Pharmacology . 61 . 263–99 . 2011 . 21586362 . 10.1016/B978-0-12-385526-8.00009-6 . 9780123855268 .
  13. Zimmermann H, Zebisch M, Sträter N . Cellular function and molecular structure of ecto-nucleotidases . Purinergic Signalling . 8 . 3 . 437–502 . September 2012 . 22555564 . 3360096 . 10.1007/s11302-012-9309-4 .
  14. Makarenkova HP, Shestopalov VI . The role of pannexin hemichannels in inflammation and regeneration . Frontiers in Physiology . 5 . 63 . 2014 . 24616702 . 10.3389/fphys.2014.00063 . 3933922 . free .
  15. Adamson SE, Leitinger N . The role of pannexin1 in the induction and resolution of inflammation . FEBS Letters . 588 . 8 . 1416–22 . April 2014 . 24642372 . 10.1016/j.febslet.2014.03.009 . 4060616 .
  16. McIntosh VJ, Lasley RD . Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? . Journal of Cardiovascular Pharmacology and Therapeutics . 17 . 1 . 21–33 . March 2012 . 21335481 . 10.1177/1074248410396877 . 544367 .
  17. Book: Mustafa SJ, Morrison RR, Teng B, Pelleg A . Adenosine Receptors and the Heart: Role in Regulation of Coronary Blood Flow and Cardiac Electrophysiology . Adenosine Receptors in Health and Disease . 193 . 193 . 161–88 . 2009 . 19639282 . 2913612 . 10.1007/978-3-540-89615-9_6 . 978-3-540-89614-2 . Handbook of Experimental Pharmacology .
  18. Colgan SP, Eltzschig HK . Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery . Annual Review of Physiology . 74 . 1 . 153–75 . 17 March 2012 . 21942704 . 3882030 . 10.1146/annurev-physiol-020911-153230 .
  19. Lohman AW, Billaud M, Isakson BE . Mechanisms of ATP release and signalling in the blood vessel wall . Cardiovascular Research . 95 . 3 . 269–80 . August 2012 . 22678409 . 3400358 . 10.1093/cvr/cvs187 .
  20. Dahl G, Muller KJ . Innexin and pannexin channels and their signaling . FEBS Letters . 588 . 8 . 1396–402 . April 2014 . 24632288 . 10.1016/j.febslet.2014.03.007 . 45630385 . free .
  21. Storey RF . New P2Y₁₂ inhibitors . Heart . 97 . 15 . 1262–7 . August 2011 . 21742618 . 10.1136/hrt.2009.184242 . 5140764 .
  22. Barn K, Steinhubl SR . A brief review of the past and future of platelet P2Y12 antagonist . Coronary Artery Disease . 23 . 6 . 368–74 . September 2012 . 22735090 . 10.1097/MCA.0b013e3283564930 . 2870694 .
  23. Oliveira AG, Marques PE, Amaral SS, Quintão JL, Cogliati B, Dagli ML, Rogiers V, Vanhaecke T, Vinken M, Menezes GB . Purinergic signalling during sterile liver injury . Liver International . 33 . 3 . 353–61 . March 2013 . 23402607 . 10.1111/liv.12109 . free .
  24. Wood JD . The enteric purinergic P2Y1 receptor . Current Opinion in Pharmacology . 6 . 6 . 564–70 . December 2006 . 16934527 . 10.1016/j.coph.2006.06.006 .
  25. Stojilkovic SS, Koshimizu T . Signaling by extracellular nucleotides in anterior pituitary cells . Trends in Endocrinology and Metabolism . 12 . 5 . 218–25 . July 2001 . 11397647 . 10.1016/S1043-2760(01)00387-3 . 21874995 . free .
  26. Junger WG . Immune cell regulation by autocrine purinergic signalling . Nature Reviews. Immunology . 11 . 3 . 201–12 . March 2011 . 21331080 . 4209705 . 10.1038/nri2938 .
  27. Web site: Final Report Summary - ATPBONE (Fighting osteoporosis by blocking nucleotides: purinergic signalling in bone formation and homeostasis). CORDIS. 4 September 2013.
  28. Jacob F, Pérez Novo C, Bachert C, Van Crombruggen K . Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses . Purinergic Signalling . 9 . 3 . 285–306 . September 2013 . 23404828 . 3757148 . 10.1007/s11302-013-9357-4 .
  29. Trautmann A . Extracellular ATP in the immune system: more than just a "danger signal" . Science Signaling . 2 . 56 . pe6 . February 2009 . 19193605 . 10.1126/scisignal.256pe6 . 42651032 .
  30. Barletta KE, Ley K, Mehrad B . Regulation of neutrophil function by adenosine . Arteriosclerosis, Thrombosis, and Vascular Biology . 32 . 4 . 856–64 . April 2012 . 22423037 . 3353547 . 10.1161/atvbaha.111.226845 .
  31. Eltzschig HK, Macmanus CF, Colgan SP . Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface . Trends in Cardiovascular Medicine . 18 . 3 . 103–7 . April 2008 . 18436149 . 2711033 . 10.1016/j.tcm.2008.01.006 .
  32. North RA, Verkhratsky A . Purinergic transmission in the central nervous system . Pflügers Archiv . 452 . 5 . 479–85 . August 2006 . 16688467 . 10.1007/s00424-006-0060-y . 25006319 .
  33. Ransohoff RM, Perry VH . Microglial physiology: unique stimuli, specialized responses . Annual Review of Immunology . 27 . 1 . 119–45 . April 2009 . 19302036 . 10.1146/annurev.immunol.021908.132528 .
  34. Fields RD, Burnstock G . Purinergic signalling in neuron-glia interactions . Nature Reviews. Neuroscience . 7 . 6 . 423–36 . June 2006 . 16715052 . 2062484 . 10.1038/nrn1928 .
  35. Cserép C, Pósfai B, Lénárt N, Fekete R, László ZI, Lele Z, Orsolits B, Molnár G, Heindl S, Schwarcz AD, Ujvári K, Környei Z, Tóth K, Szabadits E, Sperlágh B, Baranyi M, Csiba L, Hortobágyi T, Maglóczky Z, Martinecz B, Szabó G, Erdélyi F, Szipőcs R, Tamkun MM, Gesierich B, Duering M, Katona I, Liesz A, Tamás G, Dénes Á . 209343260 . 6 . Microglia monitor and protect neuronal function through specialized somatic purinergic junctions . Science . 367 . 6477 . 528–537 . January 2020 . 31831638 . 10.1126/science.aax6752 . 2020Sci...367..528C .
  36. Microglial control of neuronal development via somatic purinergic junctions . 10.1016/j.celrep.2022.111369 . 2022 . Csaba . Cserep . Anett . Schwarcz D . Cell Reports . 36130488 .
  37. Lohr C, Grosche A, Reichenbach A, Hirnet D . Purinergic neuron-glia interactions in sensory systems . Pflügers Archiv . 466 . 10 . 1859–72 . October 2014 . 24705940 . 10.1007/s00424-014-1510-6 . 18952066 .
  38. Del Puerto A, Wandosell F, Garrido JJ . Neuronal and glial purinergic receptors functions in neuron development and brain disease . Frontiers in Cellular Neuroscience . 7 . 197 . October 2013 . 24191147 . 10.3389/fncel.2013.00197 . 3808753 . free .
  39. Microglia contribute to neuronal synchrony despite endogenous ATP-related phenotypic transformation in acute mouse brain slices . 10.1038/s41467-024-49773-1 . 2024 . Peter . Berki . Csaba . Cserep . Zsuzsanna . Környei . Nature Communications . 38926390 . 11208608 .
  40. Arulkumaran N, Turner CM, Sixma ML, Singer M, Unwin R, Tam FW . Purinergic signaling in inflammatory renal disease . Frontiers in Physiology . 4 . 194 . 1 January 2013 . 23908631 . 3725473 . 10.3389/fphys.2013.00194 . Extracellular adenosine contributes to the regulation of GFR. Renal interstitial adenosine is mainly derived from dephosphorylation of released ATP, AMP, or cAMP by the enzyme ecto-5′-nucleotidase (CD73) (Le Hir and Kaissling, 1993). This enzyme catalyzes the dephosphorylation of 5′-AMP or 5′-IMP to adenosine or inosine, respectively, and is located primarily on the external membranes and mitochondria of proximal tubule cells, but not in distal tubule or collecting duct cells (Miller et al., 1978). ATP consumed in active transport by the macula densa also contributes to the formation of adenosine by 5- nucleotidase (Thomson et al., 2000). Extracellular adenosine activates A1 receptors on vascular afferent arteriolar smooth muscle cells, resulting in vasoconstriction and a reduction in GFR (Schnermann et al., 1990). . free .
  41. Ren Y, Garvin JL, Liu R, Carretero OA . Role of macula densa adenosine triphosphate (ATP) in tubuloglomerular feedback . Kidney International . 66 . 4 . 1479–85 . October 2004 . 15458441 . 10.1111/j.1523-1755.2004.00911.x . free .
  42. Lazarowski ER, Boucher RC . Purinergic receptors in airway epithelia . Current Opinion in Pharmacology . 9 . 3 . 262–7 . June 2009 . 19285919 . 2692813 . 10.1016/j.coph.2009.02.004 .
  43. Housley GD . Recent insights into the regulation of breathing . Autonomic Neuroscience . 164 . 1–2 . 3–5 . October 2011 . 21852203 . 10.1016/j.autneu.2011.08.002 . 30097466 .
  44. Rumney RM, Wang N, Agrawal A, Gartland A . Purinergic signalling in bone . Frontiers in Endocrinology . 3 . 116 . 2012 . 23049524 . 10.3389/fendo.2012.00116 . 3446723. free .
  45. Mediero A, Cronstein BN . Adenosine and bone metabolism . Trends in Endocrinology and Metabolism . 24 . 6 . 290–300 . June 2013 . 23499155 . 3669669 . 10.1016/j.tem.2013.02.001 .
  46. Wilson CN . Adenosine receptors and asthma in humans . British Journal of Pharmacology . 155 . 4 . 475–86 . October 2008 . 18852693 . 2579661 . 10.1038/bjp.2008.361 .
  47. Jørgensen NR, Adinolfi E, Orriss I, Schwarz P . Purinergic signaling in bone . Journal of Osteoporosis . 2013 . 673684 . 1 January 2013 . 23762774 . 10.1155/2013/673684 . 3671543. free .
  48. Di Virgilio F . Purines, purinergic receptors, and cancer . Cancer Research . 72 . 21 . 5441–7 . November 2012 . 23090120 . 10.1158/0008-5472.CAN-12-1600 . Editorial . free .
  49. Antonioli L, Blandizzi C, Pacher P, Haskó G . Immunity, inflammation and cancer: a leading role for adenosine . Nature Reviews. Cancer . 13 . 12 . 842–57 . December 2013 . 24226193 . 10.1038/nrc3613 . 13224098 .
  50. Reiss AB, Cronstein BN . Regulation of foam cells by adenosine . Arteriosclerosis, Thrombosis, and Vascular Biology . 32 . 4 . 879–86 . April 2012 . 22423040 . 3306592 . 10.1161/atvbaha.111.226878 .
  51. Mortaz E, Folkerts G, Nijkamp FP, Henricks PA . ATP and the pathogenesis of COPD . European Journal of Pharmacology . 638 . 1–3 . 1–4 . July 2010 . 20423711 . 10.1016/j.ejphar.2010.04.019 .
  52. Book: Esther CR, Alexis NE, Picher M . Regulation of Airway Nucleotides in Chronic Lung Diseases . Purinergic Regulation of Respiratory Diseases . 55 . 75–93 . 2011 . 21560045 . 10.1007/978-94-007-1217-1_4 . 978-94-007-1216-4 . Subcellular Biochemistry .
  53. Phatarpekar PV, Wen J, Xia Y . Role of adenosine signaling in penile erection and erectile disorders . The Journal of Sexual Medicine . 7 . 11 . 3553–64 . November 2010 . 19889148 . 10.1111/j.1743-6109.2009.01555.x . 2906687 .
  54. Wen J, Xia Y . Adenosine signaling: good or bad in erectile function? . Arteriosclerosis, Thrombosis, and Vascular Biology . 32 . 4 . 845–50 . April 2012 . 22423035 . 10.1161/atvbaha.111.226803 . free .
  55. Karmouty-Quintana H, Xia Y, Blackburn MR . Adenosine signaling during acute and chronic disease states . Journal of Molecular Medicine . 91 . 2 . 173–81 . February 2013 . 23340998 . 10.1007/s00109-013-0997-1 . 3606047 .
  56. Lu D, Insel PA . Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis . American Journal of Physiology. Cell Physiology . 306 . 9 . C779-88 . May 2014 . 24352335 . 10.1152/ajpcell.00381.2013 . 4010809 .
  57. Blazar BR, Murphy WJ, Abedi M . Advances in graft-versus-host disease biology and therapy . Nature Reviews. Immunology . 12 . 6 . 443–58 . May 2012 . 22576252 . 3552454 . 10.1038/nri3212 .
  58. Berman BM, Langevin HM, Witt CM, Dubner R . Acupuncture for chronic low back pain . The New England Journal of Medicine . 363 . 5 . 454–61 . July 2010 . 20818865 . 10.1056/NEJMct0806114 . Acupuncture also has effects on local tissues, including mechanical stimulation of connective tissue, release of adenosine at the site of needle stimulation, and increases in local blood flow .
  59. Book: Masino S, Boison D . Sawynok J. Adenosine . Adenosine and Pain . Adenosine a key link between metabolism and brain activity. 2013 . Springer. New York, NY. 978-1-4614-3903-5. 10.1007/978-1-4614-3903-5_17. in an elegant series of experiments, adenosine has been implicated as a mediator of acupuncture analgesia. 352.
  60. Gorski. David H.. Integrative oncology: really the best of both worlds?. Nature Reviews Cancer. 2014. 1474-175X. 10.1038/nrc3822. 25230880. 14. 10. 692–700. 33539406.
  61. Yang ES, Li PW, Nilius B, Li G . Ancient Chinese medicine and mechanistic evidence of acupuncture physiology . Pflügers Archiv . 462 . 5 . 645–53 . November 2011 . 21870056 . 10.1007/s00424-011-1017-3 . Anti-nociceptive effect of acupuncture requires A1 receptors . 3192271.
  62. Zylka MJ . Pain-relieving prospects for adenosine receptors and ectonucleotidases . Trends in Molecular Medicine . 17 . 4 . 188–96 . April 2011 . 21236731 . 10.1016/j.molmed.2010.12.006 . Antinociceptive effects of acupuncture require A1R activation . 3078941 .
  63. Langevin HM . Acupuncture, connective tissue, and peripheral sensory modulation . Critical Reviews in Eukaryotic Gene Expression . 24 . 3 . 249–53 . 2014 . 25072149 . 10.1615/CritRevEukaryotGeneExpr.2014008284 .
  64. Zhang R, Lao L, Ren K, Berman BM . Mechanisms of acupuncture-electroacupuncture on persistent pain . Anesthesiology . 120 . 2 . 482–503 . February 2014 . 24322588 . 10.1097/ALN.0000000000000101 . 3947586 .
  65. Chan ES, Cronstein BN . Molecular action of methotrexate in inflammatory diseases . Arthritis Research . 4 . 4 . 266–73 . 2002 . 12106498 . 128935 . 10.1186/ar419 . free .
  66. Topol EJ, Schork NJ . Catapulting clopidogrel pharmacogenomics forward . Nature Medicine . 17 . 1 . 40–1 . January 2011 . 21217678 . 10.1038/nm0111-40 . 32083067 .
  67. Barnes PJ . Theophylline . American Journal of Respiratory and Critical Care Medicine . 188 . 8 . 901–6 . October 2013 . 23672674 . 10.1164/rccm.201302-0388PP .
  68. Burnstock G . Pathophysiology and therapeutic potential of purinergic signaling . Pharmacological Reviews . 58 . 1 . 58–86 . March 2006 . 16507883 . 10.1124/pr.58.1.5 . 12337865 . Tetramethylpyrazine, a traditional Chinese medicine used as an analgesic for dysmenorrhea, was shown to block P2X3 receptor signaling . 10.1.1.623.4370 .
  69. Burnstock G . Purinergic P2 receptors as targets for novel analgesics . Pharmacology & Therapeutics . 110 . 3 . 433–54 . June 2006 . 16226312 . 10.1016/j.pharmthera.2005.08.013 .
  70. Burnstock G, Knight GE, Greig AV . Purinergic signaling in healthy and diseased skin . The Journal of Investigative Dermatology . 132 . 3 Pt 1 . 526–46 . March 2012 . 22158558 . 10.1038/jid.2011.344 . free .
  71. Liang S, Xu C, Li G, Gao Y . P2X receptors and modulation of pain transmission: focus on effects of drugs and compounds used in traditional Chinese medicine . Neurochemistry International . 57 . 7 . 705–12 . December 2010 . 20863868 . 10.1016/j.neuint.2010.09.004 . 21358206 .
  72. Zhou YX, Zhang H, Peng C . Puerarin: a review of pharmacological effects . Phytotherapy Research . 28 . 7 . 961–75 . July 2014 . 24339367 . 10.1002/ptr.5083 . 40855672 .
  73. Jiang LH, Baldwin JM, Roger S, Baldwin SA . Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms . Frontiers in Pharmacology . 4 . 55 . 2013 . 23675347 . 10.3389/fphar.2013.00055 . Natural compounds isolated from plants used in traditional medicines have also been shown to selectively inhibit the P2X7Rs . 3646254. free .
  74. Adinolfi E . New intriguing roles of ATP and its receptors in promoting tumor metastasis : presented by Maria P. Abbracchio . Purinergic Signalling . 9 . 4 . 487–90 . December 2013 . 24258487 . 10.1007/s11302-013-9401-4 . The study from Jelassi and colleagues further support these findings showing the efficacy of emodin, a Chinese traditional medicine compound, in reducing P2X7 mediated malignant progression. . 3889383.
  75. Burnstock G, Di Virgilio F . Purinergic signalling and cancer . Purinergic Signalling . 9 . 4 . 491–540 . December 2013 . 23797685 . 3889385 . 10.1007/s11302-013-9372-5 . Chrysophanol, a member of the anthraquinone family that is one of the components of a Chinese herb including rhubarb recommended for the treatment of cancer, induces necrosis of J5 human liver cancer cells via reduction in ATP levels .
  76. Chen JF, Eltzschig HK, Fredholm BB . Adenosine receptors as drug targets--what are the challenges? . Nature Reviews. Drug Discovery . 12 . 4 . 265–86 . April 2013 . 23535933 . 3930074 . 10.1038/nrd3955 .
  77. Palani G, Ananthasubramaniam K . Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications . Cardiology in Review . 21 . 1 . 42–8 . 2013 . 22643345 . 10.1097/CRD.0b013e3182613db6 . 9183656 .
  78. Cerqueira MD . The future of pharmacologic stress: selective A2A adenosine receptor agonists . The American Journal of Cardiology . 94 . 2A . 33D-40D; discussion 40D-42D . July 2004 . 15261132 . 10.1016/j.amjcard.2004.04.017 .
  79. Lau OC, Samarawickrama C, Skalicky SE . P2Y2 receptor agonists for the treatment of dry eye disease: a review . Clinical Ophthalmology . 8 . 327–34 . January 2014 . 24511227 . 3915022 . 10.2147/OPTH.S39699 . free .
  80. Chen W, Wang H, Wei H, Gu S, Wei H . Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis . Journal of the Neurological Sciences . 324 . 1–2 . 21–8 . January 2013 . 23085003 . 10.1016/j.jns.2012.08.030 . 34848760 .
  81. Eltzschig HK, Sitkovsky MV, Robson SC . Purinergic signaling during inflammation . The New England Journal of Medicine . 367 . 24 . 2322–33 . December 2012 . 23234515 . 10.1056/NEJMra1205750 . 3675791 .
  82. Drury AN, Szent-Györgyi A . The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart . The Journal of Physiology . 68 . 3 . 213–37 . November 1929 . 16994064 . 1402863 . 10.1113/jphysiol.1929.sp002608 .
  83. Campbell G . Cotransmission . Annual Review of Pharmacology and Toxicology . 27 . 1 . 51–70 . April 1987 . 2883929 . 10.1146/annurev.pa.27.040187.000411 .
  84. Martinson J, Muren A . Excitatory and inhibitory effects if vagus stimulation on gastric motility in the cat . Acta Physiol. Scand. . 57 . 1963 . 4 . 309–316 . 10.1111/j.1748-1716.1963.tb02594.x.
  85. Burnstock G, Campbell G, Bennett M, Holman ME . Inhibition of the Smooth Muscle on the Taenia Coli . Nature . 200 . 4906 . 581–2 . November 1963 . 14082235 . 10.1038/200581a0 . 1963Natur.200..581B . 4277023 .
  86. Burnstock G . Purinergic nerves . Pharmacological Reviews . 24 . 3 . 509–81 . September 1972 . 4404211 .
  87. Book: Fritz . Lipmann . 1941 . Metabolic Generation and Utilization of Phosphate Bond Energy . 10.1002/9780470122464.ch4 . Nord FF, Werkman CH . Advances in Enzymology and Related Areas of Molecular Biology . 1 . 99–162. 9780470122464 . 94733045 .
  88. Praetorius HA, Leipziger J . Intrarenal purinergic signaling in the control of renal tubular transport . Annual Review of Physiology . 72 . 1 . 377–93 . 1 March 2010 . 20148681 . 10.1146/annurev-physiol-021909-135825 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Purinergic signalling".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.